Ibrutinib for treatment of chronic lymphocytic leukemia

Vela, Cory M.; McBride, Ali; Jaglowski, Samantha; Andritsos, Leslie A.

doi:10.2146/ajhp140760

Cited by 14 publications

(8 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The most common adverse events associated with ibrutinib include diarrhea, fatigue, cough, nausea, and upper respiratory infection. Serious adverse effects usually occur infrequently and include neutropenia, diarrhea, hypertension, fatigue, and pneumonia [11]. The patient we represented in this report had experienced episodes of respiratory infection, cough, breathlessness, and pneumonia during the therapy.…”

Section: Discussionmentioning

confidence: 86%

Ibrutinib in the Management of Non-Hodgkin’s Lymphoma: A Case Report

Pavithran

2018

Asian J Pharm Clin Res

View full text Add to dashboard Cite

Non-Hodgkin's lymphoma (NHL) is a diverse group of lymphoid neoplasms, the prevalence of which has increased over the past few decades. NHL is diverse in the manner of presentation, response to various treatment and prognosis. The current case report describes a 40-year-old man who was diagnosed with small lymphocytic lymphoma/chronic lymphocytic leukemia in 2006. The patient had disease progression during the course of 10 years from the time of diagnosis for which he received multiple lines of chemotherapy (chlorambucil/prednisolone; rituximab/cyclophosphamide/ fludarabine; bendamustine/rituximab; and ofatumumab). However, in 2016, his disease again showed signs of progression, and hence he was started on ibrutinib 140 mg 3 times daily. After treatment with ibrutinib, there were no clinical nodes and hepatosplenomegaly, and all counts also normalized. Since the commencement of this agent, no disease progression was observed for almost 16 months. However, in July 2017, again disease progression occurred, and the patient was started on with cyclophosphamide, vincristine, and prednisone (COP) regimen. He received one cycle of COP regimen and continued on treatment with ibrutinib, and the treatment was well tolerated. In December 2017, he expired due to the progression of the disease. Ibrutinib, a Bruton's tyrosine kinase inhibitor, appears to be safe and effective in providing long-term disease control even in refractory cases of NHL.

show abstract

Section: Discussionmentioning

confidence: 86%

Ibrutinib in the Management of Non-Hodgkin’s Lymphoma: A Case Report

Pavithran

2018

Asian J Pharm Clin Res

View full text Add to dashboard Cite

show abstract

“…Relatively smaller numbers of patients received rituximab-containing chemotherapy as first-, or second-line chemotherapy in our data. Nowadays, several novel agents including the Bruton's tyrosine kinase inhibitor (ibrutinib), anti-CD20 monoclonal antibody (obinutuzumab), bendamustine, and ofatumumab have been introduced as first-line therapy for CLL [8,[17][18][19]. Unfortunately, the national medical insurance reimbursement system in Korea does not cover the expenses for the procurement of those novel agents as first-line chemotherapy for CLL.…”

Section: Discussionmentioning

confidence: 99%

Treatment outcome and prognostic factors of Korean patients with chronic lymphocytic leukemia: a multicenter retrospective study

Choi

Lee

Jung

et al. 2021

Korean J Intern Med

View full text Add to dashboard Cite

Background/Aims: Compared with Western countries, chronic lymphocytic leukemia (CLL) rarely occurs in Asia and has different clinical characteristics. Thus, we aimed to evaluate the clinical characteristics, treatment outcomes, and prognostic significance of Korean patients with CLL. Methods: We retrospectively analyzed 90 patients with CLL who had received chemotherapy at 6 centers in Korea between 2000 and 2012. Results: Compared with Western patients with CLL, Korean patients with CLL express lambda (42.0%) and atypical markers such as CD22 and FMC7 (76.7% and 40.0%, respectively) more frequently. First-line chemotherapy regimens included chlorambucil (n = 43), fludarabine and cyclophosphamide (FC) (n = 20), fludarabine (n = 13), rituximab-FC (n = 4). The remaining patients were treated with other various regimens (n = 10). The 5-year overall survival (OS) and progression-free survival (PFS) rates were 79.3% and 28.1%, respectively. Multivariate analyses showed that hyperleukocytosis (≥ 100 × 10 3 /μL), extranodal involvement, and the Binet C stage were significant negative prognostic factors for OS (hazard ratio [HR] 4.75, p = 0.039; HR 21.6, p = 0.002; and HR 4.35, p = 0.034, respectively). Cytogenetic abnormalities including complex karyotypes (≥ 3), del(11q), and del(17) had a significantly adverse impact on both OS and PFS (p < 0.001 and p = 0.010, respectively). Conclusions: Initial hyperleukocytosis, extranodal involvement, complex karyotype, del(17) and del(11q) need to be considered in the risk stratification system for CLL.

show abstract

“…It has been approved for the treatment of metastatic colon cancer and metastatic kidney cancer as well as non-small cell lung cancer and glioblastoma. Due to the antiangiogenic mechanism of this agent it may reduce wound healing and should not be used soon after surgery (20)(21)(22); (iii) Panitumumab which is a human IgG2 kappa MAB is used to eradicate metastatic colon cancer expressing epidermal growth factor receptor (EGFR) which has been unresponsive to traditional chemotherapy (23)(24)(25); (iv) Cetuximab a human/mouse chimeric MAB, which also binds to and inactivates the EGFR, is used in the treatment of EGFR-positive colon cancer and also for head and neck cancers (24)(25)(26); (v) Ofatumumab is a human IgG1 MAB used in patients with chronic lymphocytic leukemia who are unresponsive to chemotherapy (27)(28)(29)(30) ; (vi) Trastuzumab is a humanized MAB that acts at extracellular HER-2/neu which impedes ERGR activity. This agent is used in patients with HER-2/neu-positive breast cancer and metastatic gastrointestinal (GI) cancers and in patients with other forms of cancer that express HER-2/neu (31-34); (vii) Rituximab is a human/murine MAB that has been approved for the treatment of non-Hodgkin's lymphoma and also lymphocytic leukemia.…”

Section: Antitumor Monoclonal Antibodies (Mabs)mentioning

confidence: 99%

Monoclonal Antibodies for the Treatment of Cancer

Pento

2017

View full text Add to dashboard Cite

Abstract.Cancer metastasis is responsible for most of the morbidity and mortality associated with cancer. Cancer metastatic progression is a multiple step process which includes enhanced cell proliferation, release of proteolytic enzymes, cell motility and invasion, angiogenesis and establishment of a supportive microenvironment at the sites of metastatic growth (1, 2).Traditional cancer therapy has focused on removal or destruction of tumour cells by surgery, radiation and rather nonselective types of chemotherapy. Surgery and radiation are often effective with tumours which are localized and have not metastasized to multiple sites throughout the body. Chemotherapy appears to be most effective in the treatment of metastatic cancer; however, typical chemotherapeutic agents such as cisplatin, methotrexate, vincristine, 5-fluorouracil among many others, focus on rapidly growing tissues since cancer cells are relatively rapidly growing. Thus, cancer chemotherapy often results in a high incidence of unwanted and damaging side-effects in rapidly-dividing normal tissues, such as blood cells and cells lining gastrointestinal tract.With a greater understanding of cellular chemistry and genomics during the past twenty years, cellular targets that are unique to cancer cells have been identified and chemotherapeutic agents which specifically bind to, destroy or otherwise inactivate these unique cellular targets have been developed. These agents which impede these unique or overexpressed cancer targets tend to be more selective, -thus more effective with fewer side-effects than traditional, nonselective chemotherapy. They target critical checkpoints which are often overexpressed on rapidly growing and malignant cancer cells, such as vascular endothelial growth factor (VEGF), epidermal growth factor (EGF) and tyrosine kinase. Therefore, cancer Immunotherapy is an exciting and relatively new method to selectively block critical checkpoints in the process of cancer development (3, 4).

show abstract

Ibrutinib for treatment of chronic lymphocytic leukemia

Cited by 14 publications

References 35 publications

Ibrutinib in the Management of Non-Hodgkin’s Lymphoma: A Case Report

Ibrutinib in the Management of Non-Hodgkin’s Lymphoma: A Case Report

Treatment outcome and prognostic factors of Korean patients with chronic lymphocytic leukemia: a multicenter retrospective study

Monoclonal Antibodies for the Treatment of Cancer

Contact Info

Product

Resources

About